Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.
Impact
The proposed legislation would significantly affect health insurance coverage by establishing a clear limit on patient costs for critical asthma care equipment. By capping the co-pay amount, S2876 endeavors to enhance accessibility to necessary treatments, ensuring that financial barriers do not prevent individuals from acquiring life-saving medications. This move aims to promote healthier outcomes for those suffering from asthma and related respiratory issues, aligning with broader public health objectives.
Summary
Bill S2876, introduced in the Rhode Island General Assembly, seeks to enact a cap on the amount a covered individual must pay for prescription inhalers and related devices or equipment used for administering inhaled medications. Specifically, the bill stipulates that the out-of-pocket cost for these prescription items shall not exceed $25 for a thirty-day supply. This legislative initiative aims to mitigate the financial burden of essential asthma medications and devices on individuals who rely on them for managing their respiratory conditions.
Contention
While the bill has garnered support for its intent to alleviate healthcare costs, there are potential points of contention regarding its implementation and the effects on insurance providers. Critics might voice concerns about how this cap may affect overall insurance premiums or coverage policies, as insurers would need to adjust their pricing models to accommodate the new cost-sharing structure stipulated by the bill. Additionally, ensuring compliance from insurance providers and distributing clear guidelines regarding coverage and copayment exemptions will be vital to the bill's success.
Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.
Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.